Hyperphosphatemia Therapeutics Market Size, Share, and Outlook: Forecast Trends and Growth Analysis Report (2026-2035)

Global Market Likely to be Driven by Need for Effective Treatment for Hyperphosphatemia

Hyperphosphatemia refers to serum phosphate concentration > 4.5 mg/dL (> 1.46 mmol/L). Metabolic or respiratory acidosis, Chronic kidney disease, and hypoparathyroidism could be possible causes. Serum phosphate measurement is carried out for diagnosis. Treatment may comprise limited intake of phosphate and taking phosphate-binding antacids, like calcium carbonate.

Reduced renal excretion of phosphate may generally be a cause of hyperphosphatemia. Hyperphosphatemia irregularly caused by a large transcellular movement of phosphate into the extracellular space, overwhelming the renal excretory capacity. Such transcellular movement frequently takes place in diabetic ketoacidosis, nontraumatic rhabdomyolysis, crush injuries, overwhelming systemic infections, tumour lysis syndrome. Hyperphosphatemia may also take place due to excessive oral phosphate administration, and, at times, with overuse of enemas carrying phosphate.

Advancements in Drug Development Likely to Boost Market Growth

Advancements in research and treatment systems are expected to drive the global hyperphosphatemia therapeutics market. For example, in 2023, it was reported that Lupin had launched Sevelamer Hydrochloride tablets (800 mg) – a medicine employed to treat hyperphosphatemia in individuals suffering from chronic kidney disease – in USA. The product had been introduced after obtaining USFDA approval.

In 2021, it was reported that individuals with chronic kidney disease on maintenance dialysis felt enhanced control of hyperphosphatemia when a dual treatment comprising tenapanor and phosphate binders was administered as against the administration of only phosphate binders or only tenapanor.

In 2020, Unicycive Therapeutics acquired Renazorb (Lanthanum Dioxycarbonate) from Spectrum Pharmaceuticals for the treatment of hyperphosphatemia in individuals with chronic kidney disease. Renazorb has exhibited distinct phosphate binding features with the potential to treat hyperphosphatemia in chronic kidney disease patients with significant patient adherence advantages including smaller and lesser pills per dose than current care standards. Such developments are expected to boost the global hyperphosphatemia therapeutics market.

In 2020, Ardelyx, Inc. announced the submission of New Drug Application (NDA) for tenapanor to USFDA for regulation of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.

Market Segmentation

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Key Industry Players in the Market

The report offers an extensive assessment of major players in the global hyperphosphatemia therapeutics market; it evaluates their capability, observes latest occurrences such as mergers and acquisitions, capacity expansions, and plant turnarounds:

• Astellas Pharma Inc.
• Akebia Therapeutics, Inc
• Lupin Limited
• Ardelyx, Inc
• Vifor Pharma Management Ltd.
• Others

Using SWOT analysis and Porter’s Five Forces model, the EMR report offers deep insights into the industry.